Everstar Asset Management LLC Purchases Shares of 15,468 Edwards Lifesciences Corporation $EW

Key Points

• Everstar Asset Management LLC purchased 15,468 shares of Edwards Lifesciences Corporation in Q1, valued at approximately $1.12 million, highlighting institutional interest in the company.
• Analysts have raised price targets for the stock, with Citigroup setting a target of $95.00, indicating strong confidence in its performance.
• Edwards Lifesciences reported earnings per share of $0.67 for the last quarter, surpassing expectations and signaling an 11.9% year-over-year revenue growth.

Everstar Asset Management LLC acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 15,468 shares of the medical research company's stock, valued at approximately $1,121,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Allspring Global Investments Holdings LLC increased its stake in Edwards Lifesciences by 0.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after buying an additional 145 shares in the last quarter. Dynamic Advisor Solutions LLC lifted its holdings in Edwards Lifesciences by 2.4% in the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock valued at $1,124,000 after acquiring an additional 370 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Edwards Lifesciences by 13.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock valued at $5,582,000 after acquiring an additional 9,188 shares during the last quarter. United Asset Strategies Inc. lifted its holdings in Edwards Lifesciences by 10.4% in the first quarter. United Asset Strategies Inc. now owns 185,571 shares of the medical research company's stock valued at $13,450,000 after acquiring an additional 17,412 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in Edwards Lifesciences by 390.7% during the first quarter. Farther Finance Advisors LLC now owns 8,808 shares of the medical research company's stock worth $633,000 after purchasing an additional 7,013 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insider Activity

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at approximately $15,565,087. This represents a 4.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 22,014 shares of company stock valued at $1,698,844. 1.29% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Evercore ISI upped their price objective on Edwards Lifesciences from $77.00 to $80.00 and gave the stock an "in-line" rating in a research report on Friday, July 25th. Royal Bank Of Canada raised their price objective on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Truist Financial increased their target price on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a research note on Friday, July 25th. Wells Fargo & Company increased their target price on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a research note on Thursday, August 7th. Finally, Deutsche Bank Aktiengesellschaft raised their price objective on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a research report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of "Moderate Buy" and an average target price of $86.26.

Edwards Lifesciences Stock Down 0.7%

Edwards Lifesciences stock traded down $0.51 during trading on Friday, reaching $77.50. 6,301,589 shares of the company's stock were exchanged, compared to its average volume of 3,595,766. Edwards Lifesciences Corporation has a 52-week low of $64.00 and a 52-week high of $83.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The firm has a market cap of $45.50 billion, a price-to-earnings ratio of 11.15, a PEG ratio of 3.76 and a beta of 1.07. The company's 50-day moving average is $78.92 and its two-hundred day moving average is $75.42.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm's revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.